Targeting Checkpoint Kinase 1 in Cancer Therapeutics

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-2793
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Targeting Microenvironment in Cancer Therapeutics

Oncotarget
Oncology
2016English

Direct Therapeutic Targeting of Immune Checkpoint PD-1 in Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Therapeutic Targeting of Casein Kinase 1 in Breast Cancer

Science Translational Medicine
Medicine
2015English

Targeting Tumor Suppressor Networks for Cancer Therapeutics

Current Drug Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2014English

Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics

International Journal of Cell Biology
Cell Biology
2015English

Differential Roles of Checkpoint Kinase 1, Checkpoint Kinase 2, and Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Mediating DNA Damage-Induced Cell Cycle Arrest: Implications for Cancer Therapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Targeting Genetic Alterations in Protein Methyltransferases for Personalized Cancer Therapeutics

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Cancer Therapeutics

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Targeting Focal Adhesion Kinase Reprograms the Pancreatic Tumor Microenvironment and Renders Pancreas Cancer Responsive to Checkpoint Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy